Search research articles
Contact Us
Filters
Showing results (1-10 of 47) with videos related to
Page
of 5
Sort By:
Haematologica
|
June 26, 2025
Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?
Lee Mozessohn, Rena Buckstein
Blood Advances
|
May 2, 2025
Finding the right fit: assessment of fitness in AML
Nicholas Chornenki, Lee Mozessohn
Leukemia & Lymphoma
|
July 1, 2024
Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting
Joel George, Lee Mozessohn, Philip W Lam
BMJ Case Reports
|
July 12, 2012
Polyneuropathy: a poetic diagnosis
Reena Pattani, Dmitry Rozenberg, Lee Mozessohn, et al.
British Journal of Clinical Pharmacology
|
March 18, 2025
Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency
Annie Siyu Wu, Lee Mozessohn, Richard B Kim, et al.
Blood Advances
|
November 29, 2023
A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML
Mithunan Ravindran, Lee Mozessohn, Matthew Cheung, et al.
Annals of Hematology
|
November 28, 2022
EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia
Adam Suleman, Hubert Tsui, Zeina Ghorab, et al.
Sexually Transmitted Diseases
|
October 6, 2005
Factors affecting knowledge of sexually transmitted infection transmissibility in healthcare providers: results from a national survey
Natalie O Rosen, Bärbel Knäuper, Lee Mozessohn, et al.
Journal of the National Cancer Institute
|
October 22, 2016
The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study
Lee Mozessohn, Craig Earle, David Spaner, et al.
JCO Oncology Practice
|
September 21, 2020
Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia
Lee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Page
of 5
Search research articles
Search
Showing results (1-10 of 47) with videos related to
Sort By:
Page
of 5
Haematologica
|
June 26, 2025
Should we move past erythropoietin-stimulating agent monotherapy in lower-risk myelodysplastic syndromes?
Lee Mozessohn, Rena Buckstein
Blood Advances
|
May 2, 2025
Finding the right fit: assessment of fitness in AML
Nicholas Chornenki, Lee Mozessohn
Leukemia & Lymphoma
|
July 1, 2024
Cytomegalovirus infection risk with alemtuzumab therapy in hematological malignancies: a retrospective cohort study in the non-transplant setting
Joel George, Lee Mozessohn, Philip W Lam
BMJ Case Reports
|
July 12, 2012
Polyneuropathy: a poetic diagnosis
Reena Pattani, Dmitry Rozenberg, Lee Mozessohn, et al.
British Journal of Clinical Pharmacology
|
March 18, 2025
Severe myelosuppression and alopecia after thiopurine initiation in a patient with NUDT15 deficiency
Annie Siyu Wu, Lee Mozessohn, Richard B Kim, et al.
Blood Advances
|
November 29, 2023
A Markov analysis of azacitidine and venetoclax vs induction chemotherapy for medically fit patients with AML
Mithunan Ravindran, Lee Mozessohn, Matthew Cheung, et al.
Annals of Hematology
|
November 28, 2022
EBV-positive diffuse large B-cell lymphoma following alemtuzumab therapy for T-cell prolymphocytic leukemia
Adam Suleman, Hubert Tsui, Zeina Ghorab, et al.
Sexually Transmitted Diseases
|
October 6, 2005
Factors affecting knowledge of sexually transmitted infection transmissibility in healthcare providers: results from a national survey
Natalie O Rosen, Bärbel Knäuper, Lee Mozessohn, et al.
Journal of the National Cancer Institute
|
October 22, 2016
The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study
Lee Mozessohn, Craig Earle, David Spaner, et al.
JCO Oncology Practice
|
September 21, 2020
Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia
Lee Mozessohn, Matthew C Cheung, Nicole Mittmann, et al.
Page
of 5